{"type":"rich","version":"1.0","title":"How Boehringer Ingelheim is buttressing its US business ","author_name":"The Top Line","author_url":"https://www.fiercebiotech.com/podcasts","provider_name":"Omny Studio","provider_url":"https://omny.fm","html":"<iframe src=\"https://omny.fm/shows/the-top-line/how-boehringer-ingelheim-is-buttressing-its-us-business/embed\" width=\"100%\" height=\"180\" allow=\"autoplay; clipboard-write; fullscreen\" allowfullscreen frameborder=\"0\" title=\"How Boehringer Ingelheim is buttressing its US business \"></iframe>","width":600,"height":180}